Prescient Therapeutics Limited (ASX:PTX – Get Free Report) insider Gavin Shepherd purchased 614,092 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was bought at an average cost of A$0.04 ($0.03) per share, with a total value of A$26,405.96 ($16,819.08).
Prescient Therapeutics Price Performance
The company has a market cap of $38.66 million, a PE ratio of -4.69 and a beta of 1.19. The company has a debt-to-equity ratio of 1.83, a current ratio of 8.08 and a quick ratio of 17.31.
About Prescient Therapeutics
Featured Articles
- Five stocks we like better than Prescient Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Stock Analyst Ratings and Canadian Analyst Ratings
- 3 Must-Own Stocks to Build Wealth This Decade
- Breakout Stocks: What They Are and How to Identify Them
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Prescient Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prescient Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.